Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis

Anti-Cancer Drugs

Volumn 17, Issue 5, 2006, Pages 587-595

  Batist, Gerald ^a   Harris, Lyndsay ^b   Azarnia, Nozar ^b   Lee, Lily Waiyee ^b   Daza Ramirez, Pascual ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

Anthracycline retreatment; Cardiotoxicity; Liposomal doxorubicin

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; INFORMATION PROCESSING; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK REDUCTION; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

EID: 33748196550     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200606000-00014     Document Type: Article

References (29)

1. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7:560-571.
2. Cowan JD, Neidhart J, McClure S, Coltman Jr CA, Gumbart C, Martino S, et al. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer. J Natl Cancer Inst 1991; 83:1077-1084.
3. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17:2341-2354.
4. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer. J Clin Oncol 2000; 18:724-733.
5. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer. J Clin Oncol 2000; 18:2385-2394.
6. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 1988; 6:679-688.
7. Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. J Clin Oncol 1988; 6:976-982.
8. Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6:1611-1620.
9. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15:1318-1332.
10. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63:827-834.
11. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
12. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82:1109-1118.
13. Pharmacia. Adriamycin® (doxorubicin hydrochloride) US full prescribing information. Kalamazoo: Pharmacia; 2000. http://www.pharmacia.com/ products/pharm.asp.
14. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, et al. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 1989; 23:81-86.
15. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin versus free doxorubicin in beagle dogs. In Vivo 1993; 7:17-26.
16. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-1454.
17. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicentre trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25-36.
18. Swenson CE, Perkins WR, Roberts R, Janoff AS. Liposome technology and the development of Myocet (liposomal doxorubicin citrate). Breast 2001; 2(Suppl):1-7.
19. Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother 2002; 3:1739-1751.
20. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LR, et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & US Breast Intergroup. In: Program/Proceedings of the 27th Annual Meeting of the San Antonio Breast Cancer Symposium; 2004. poster 29.
21. Swenson CE, Bolcsak LE, Batist G, Guthrie Jr TH, Tkaczuk KH, Boxenbaum H, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003; 14:239-246.
22. Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 2002; 13:910-918.
23. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22:3893-3901.
24. 2. Ann Oncol 2000; 11:1029-1033.
25. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136:1475-1480.
26. Pouillart P. Evaluating the role of dexrazoxane as a cardioprotectant in cancer = patients receiving anthracyclines. Cancer Treat Rev 2004; 30:643-650.
27. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.
28. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
29. Cortes J, Climent M, Lluch A, Hornedo J, et al. Updated results of a phase II study (M77035) of Myocet combined with weekly Herceptin and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC). In: Program/Proceedings of the 27th Annual Meeting of the San Antonio Breast Cancer Symposium; 2004. poster 3041.